United Engine Corporation: Russian-French SaM146 engine surpasses 600,000 flight hours
The Russian-French SaM146 engine that powers Sukhoi Superjet 100 (SSJ100) airliners has logged over 620 thousand flight hours in operation. The SaM146 engine, produced within the 50/50 partnership between Safran and UEC, is successfully operated all around the world by well-known airlines such Russian Aeroflot, Mexican Interjet and Irish CityJet.
UEC and Safran, PowerJet mother companies, are both exhibiting SaM146 engines at their respective stands at Paris Air Show 2017 in Le Bourget (France).
SaM146 is an integrated power plant which includes the engine and the nacelle equipped by a thrust reverser. The deliveries of SaM146 and all the after-sales services are performed by PowerJet, a joint venture formed on the principles of equal representation by Safran Aircraft Engines and Russian UEC-Saturn (a part of the United Engine Corporation, UEC). UEC-Saturn is a developer and producer of the fan, the low-pressure compressor and the low-pressure turbine, and is also responsible for the final engine assembly and its testing. Safran Aircraft Engines is a developer and producer of the high-pressure compressor, the combustion chamber, the high-pressure turbine, the gearbox, the FADEC system. The French company also performs the overall integration of the power plant and is responsible for the final engine assembly and ground tests.
The leading engine of Yakutia Airline has reached 7,800 flight hours; the leading Interjet engine has surpassed 6,400 flight cycles.
Since starting revenue service in 2011, the SaM146 engine has demonstrated the exceptional performance in service, with an engine dispatch reliability of 99,9%. Such performance is based on Safran Aircraft Engines and UEC experience in commercial engines to develop the SaM146. Its optimised design improves performance and facilitates on wing maintenance to keep up with the best rate of availability.
SaM146-powered SSJ100 are currently used by 15 operators. Some of them are conducting very intensive operations in harsh environments
In order to build the world class after-sales support system, two spare part distribution centres are operating in Russia (Lytkarino) and France (Villaroche). Such localisation of the warehouses lets us to deliver spare parts practically anywhere around the world in 24 hours. Two training facilities for airlines' technical personnel also function there. The round the clock customer support centre and a web-portal are also in operation.
The SaM146 is offered in two versions which are developed and certified in accordance with the Russian and European requirements: 1S17 and 1S18 for SSJ100-95B, SSJ100-95LR and SSJ100 B100 planes, 1S17С and 1S18С for VIP-versions of SSJ100.
UEC (United Engine Corporation, a part of the Rostec State Corporation) is specialising in development, serial production, service and support of engines for military and civil aviation, space programmes and navy, as well as oil and gas industry and power generation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170621005657/en/
Contact information
United Engine Corporation
Alexander Artyukhov
press@uecrus.com
Tel.
+7 (499) 558-38-83
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release
Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release
HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom